Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109849
Title:
Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli.
Authors:
Littler, Edward; Newman, William G; Arrand, John R
Abstract:
A bacterial expression system which produces large amounts of the Epstein-Barr-virus-coded thymidine kinase has been developed and used to produce protein for Western blot analysis of a number of human antisera. Interestingly, only sera from nasopharyngeal carcinoma (NPC) patients had any detectable IgA antibody which reacted with the EBV TK. These findings provided the basis for ELISA tests using a crude lysate of the E. coli cells expressing the EBV TK as target antigen. Sera from NPC patients showed high levels of IgA reactive antibodies in this test while other sera did not.
Affiliation:
Cancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
Citation:
Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli. 1990, 45 (6):1028-32 Int. J. Cancer
Journal:
International Journal of Cancer.
Issue Date:
15-Jun-1990
URI:
http://hdl.handle.net/10541/109849
DOI:
10.1002/ijc.2910450608
PubMed ID:
2161795
Type:
Article
Language:
en
ISSN:
0020-7136
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLittler, Edwarden
dc.contributor.authorNewman, William Gen
dc.contributor.authorArrand, John Ren
dc.date.accessioned2010-08-18T13:18:10Z-
dc.date.available2010-08-18T13:18:10Z-
dc.date.issued1990-06-15-
dc.identifier.citationImmunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli. 1990, 45 (6):1028-32 Int. J. Canceren
dc.identifier.issn0020-7136-
dc.identifier.pmid2161795-
dc.identifier.doi10.1002/ijc.2910450608-
dc.identifier.urihttp://hdl.handle.net/10541/109849-
dc.description.abstractA bacterial expression system which produces large amounts of the Epstein-Barr-virus-coded thymidine kinase has been developed and used to produce protein for Western blot analysis of a number of human antisera. Interestingly, only sera from nasopharyngeal carcinoma (NPC) patients had any detectable IgA antibody which reacted with the EBV TK. These findings provided the basis for ELISA tests using a crude lysate of the E. coli cells expressing the EBV TK as target antigen. Sera from NPC patients showed high levels of IgA reactive antibodies in this test while other sera did not.en
dc.language.isoenen
dc.subjectNasopharyngeal Canceren
dc.subject.meshAntibodies, Viral-
dc.subject.meshAntibody Specificity-
dc.subject.meshBlotting, Western-
dc.subject.meshEnzyme-Linked Immunosorbent Assay-
dc.subject.meshEscherichia coli-
dc.subject.meshGene Expression Regulation, Bacterial-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin A-
dc.subject.meshNasopharyngeal Neoplasms-
dc.subject.meshPlasmids-
dc.subject.meshProtein Conformation-
dc.subject.meshRecombinant Proteins-
dc.subject.meshThymidine Kinase-
dc.subject.meshViral Proteins-
dc.titleImmunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.en
dc.identifier.journalInternational Journal of Cancer.en

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.